Trial · NCT07889999
Clinical Profile of Patients With MASLD in Kazakhstan and Clinical Effectiveness of Ursosan in Almaty
NCT07889999, Recruiting, Kazakh Association of Internal Medicine Specialists
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Clinical Profile of Patients With MASLD in Kazakhstan and Clinical Effectiveness of Ursosan in Almaty. Trials, record NCT07889999. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07889999
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical Profile of Patients With MASLD in Kazakhstan and Clinical Effectiveness of Ursosan in Almaty
- NCT number
- NCT07889999
- Status
- Recruiting
- Enrollment
- 420 participants, estimated
- Lead sponsor
- Kazakh Association of Internal Medicine Specialists
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease
- First posted
- 2026-10-22
- Last updated
- 2026-10-22
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of Participants With Hepatic Steatosis According to Imaging | 1 to 7 days | Proportion of participants with MASLD who have hepatic steatosis according to available imaging results. |
| Primary | Proportion of Participants With Liver Fibrosis According to FibroScan | 1 to 7 days | Proportion of participants with MASLD who have liver fibrosis according to FibroScan results. |
| Primary | Proportion of Participants With Liver Cirrhosis According to FibroScan | 1 to 7 days | Proportion of participants with MASLD who have liver cirrhosis according to FibroScan results. |
| Primary | Proportion of Participants With at Least 30% Reduction in ALT From Baseline | 6 months ± 2 weeks | Proportion of participants in the prospective cohort with a decrease in alanine aminotransferase (ALT) of at least 30% from the baseline value at approximately 6 months. |
| Secondary | Proportion of Participants With Abnormal Laboratory Parameters | 1 to 7 days | Proportion of participants with abnormalities in red blood cell count, hemoglobin, leukocytes, platelets, ALT, AST, GGT, bilirubin fractions, alkaline phosphatase, total cholesterol, HDL-C, LDL-C, triglycerides, creatinine, glucose, albumin, insulin, INR, and AFP. |
| Secondary | Proportion of Participants With Cardiometabolic Risk Factors | 1 to 7 days | Proportion of participants with cardiometabolic risk factors, including overweight or obesity; hyperglycemia or type 2 diabetes; triglycerides ≥1.7 mmol/L (≥150 mg/dL) or lipid-lowering treatment; HDL-C ≤1.0 mmol/L (≤39 mg/dL) in men or ≤1.3 mmol/L (≤50 mg/dL) in women or lipid-lowering treatment; and blood pressure ≥130/85 mmHg or treatment for hypertension. |
| Secondary | Proportion of Participants by Eating Behavior Profile Based on the DEBQ | 1 to 7 days | Proportion of participants with different eating behavior profiles according to the Dutch Eating Behavior Questionnaire (DEBQ). |
| Secondary | Proportion of Participants by Degree of Alcohol Misuse Based on AUDIT | 1 to 7 days | Proportion of participants with different degrees of alcohol misuse according to the Alcohol Use Disorders Identification Test (AUDIT). |
| Secondary | Prevalence of Concomitant Diseases in Participants With MASLD | 1 to 7 days | Prevalence of concomitant diseases among participants with MASLD. |
| Secondary | Prevalence of Medication and Dietary Supplement Use in Participants With MASLD | 1 to 7 days | Prevalence of individual medication classes, active substances, and dietary supplements used as current therapy among participants with MASLD. |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07889999
GET https://conductscience.org/api/trials/v1/NCT07889999/registered